Cytheris SA Announces Publication of IL-7 Oncology Data in The Journal of Experimental Medicine

Published: Jun 26, 2008

PARIS--(BUSINESS WIRE)--Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of data from a phase 1 dose escalation study evaluating the effects of IL-7 therapy on human lymphocytes in subjects with non-hematologic, non-lymphoid cancer refractory to standard therapy. The results of this study, performed in collaboration with U.S. National Cancer Institute (NCI) investigators lead by Claude Sport├Ęs, Crystal Mackall and Ronald Gress, support the potential of the IL-7 investigational product as an immunotherapy for the treatment of patients with impaired immunity due to physiologic (age), iatrogenic (chemotherapy or transplantation) or pathologic (HIV) lymphodepletion.

Back to news